0.0327

18.25% -0.0073

Gamida Cell Ltd (GMDA)

Overview News Price History Option Chain Why GMDA Down? Discussions Forecast

Gamida Cell Ltd stock is currently priced at $0.0327, with a 24-hour trading volume of 20.92M. It has seen a -18.25% decreased in the last 24 hours and a -90.47% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.0402 pivot point. If it approaches the $0.0303 support level, significant changes may occur.

Previous Close:

$0.04

Open:

$0.0395

24h Volume:

20.92M

Market Cap:

$5.04M

Revenue:

Net Income/Loss:

$-63.00M

P/E Ratio:

-0.0282

EPS:

-1.16

Net Cash Flow:

$-80.20M

1W Performance:

+0.00%

1M Performance:

-90.47%

6M Performance:

-95.75%

1Y Performance:

-97.88%

1D Range:

$0.032

$0.0395

52W Range:

$0.0303

$2.51

Gamida Cell Ltd Stock (GMDA) Company Profile

Name

Gamida Cell Ltd

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

972 2 659 5666

Address

5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem

Employee

Twitter

@GamidaCellTx

Next Earnings Date

2024-03-27

Latest SEC Filings

GMDA's Discussions on Twitter

Gamida Cell Ltd Stock (GMDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-21	Initiated	Alliance Global Partners	Buy
Jul-01-20	Initiated	Evercore ISI	Outperform
May-26-20	Initiated	Piper Sandler	Overweight
Apr-27-20	Initiated	H.C. Wainwright	Buy
Nov-26-18	Initiated	Needham	Buy
Nov-21-18	Initiated	Oppenheimer	Outperform
Nov-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Gamida Cell Ltd Stock (GMDA) Latest News

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Benzinga

Analyzing Different Penny Stocks Sectors for Profits

PennyStocks

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

US Stocks Flat; Initial Jobless Claims Fall To 210,000

Benzinga

Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Benzinga

Gamida Cell Ltd Stock (GMDA) Financials Data

Gamida Cell Ltd (GMDA) Net Income 2024

GMDA net income (TTM) was -$63.00 million for the quarter ending December 31, 2023, a +20.63% increase year-over-year.

Gamida Cell Ltd (GMDA) Cash Flow 2024

GMDA recorded a free cash flow (TTM) of -$80.20 million for the quarter ending December 31, 2023, a -4.46% decrease year-over-year.

Gamida Cell Ltd (GMDA) Earnings per Share 2024

GMDA earnings per share (TTM) was -$0.63 for the quarter ending December 31, 2023, a +48.78% growth year-over-year.

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.